Peter Chater

Dr. Peter Chater


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2012 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MAMahmoud S. Ali
Mahmoud S. Ali
SPShruti Parikh
Shruti Parikh
PCPeter Chater
Peter Chater
JPJeffrey P. Pearson
Jeffrey P. Pearson

12 June 2024 in Polymers
Verified
Journal Article
Open access
PDF file
KSKyle Jordan Stanforth
Kyle Jordan Stanforth
MZMaria Ibrahim Zakhour
Maria Ibrahim Zakhour
PCPeter Chater
Peter Chater
MWMatthew D. Wilcox
Matthew D. Wilcox
BABeth Adamson
Beth Adamson
JPJeffrey P. Pearson
Jeffrey P. Pearson
MUC2 mucin, the primary gel-forming component of intestinal mucus, is well researched and a model of polymerisation and post-secretory organisation has been published previously. Recently, several significant developments have been made which either introduce new ideas or challenge previous theories. New ideas include an overhaul of the MUC2 C-terminal globular structure which is proposed to harbour several previously unobserved domains, and include a site for an extra intermolecular disulphide bridge dimer between the cysteine 4379 of adjacent MUC2 C-termini. MUC2 polymers are also now thought to be secreted attached to the epithelial surface of goblet cells in the small intestine and removed following secretion via a metalloprotease meprin β-mediated cleavage of the von Willebrand D2 domain of the N-terminus. It remains unclear whether MUC2 forms intermolecular dimers, trimers, or both, at the N-termini during polymerisation, with several articles supporting either trimer or dimer formation. The presence of a firm inner mucus layer in the small intestine is similarly unclear. Considering this recent research, this review proposes an update to the previous model of MUC2 polymerisation and secretion, considers conflicting theories and data, and highlights the importance of this research to the understanding of MUC2 mucus layers in health and disease.

9 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLucy I. Crouch
Lucy I. Crouch
MLMarcelo V. Liberato
Marcelo V. Liberato
PUPaulina A. Urbanowicz
Paulina A. Urbanowicz
ABArnaud Baslé
Arnaud Baslé
CLChristopher A. Lamb
Christopher A. Lamb
DBDavid N. Bolam
David N. Bolam
The human gut microbiota (HGM) are closely associated with health, development and disease. The thick intestinal mucus layer, especially in the colon, is the key barrier between the contents of the lumen and the epithelial cells, providing protection against infiltration by the microbiota as well potential pathogens. The upper layer of the colonic mucus is a niche for a subset of the microbiota which utilise the mucin glycoproteins as a nutrient source and mucin grazing by the microbiota appears to play a key role in maintaining barrier function as well as community stability. Despite the importance of mucin breakdown for gut health, the mechanisms by which gut bacteria access this complex glycoprotein are not well understood. The current model for mucin degradation involves exclusively exo-acting glycosidases that sequentially trim monosaccharides from the termini of the glycan chains to eventually allow access to the mucin peptide backbone by proteases. However, this model is in direct contrast to the Sus paradigm of glycan breakdown used by the Bacteroidetes which involves extracellular cleavage of glycans by surface located endo-acting enzymes prior to import of the oligosaccharide products. Here we describe the discovery and characterisation of endo-acting family 16 glycoside hydrolases (GH16s) from prominent mucin degrading gut bacteria that specifically target the oligosaccharide side chains of intestinal mucins from both animals and humans. These endo-acting O-glycanases display β1,4-glactosidase activity and in several cases are surface located indicating they are involved in the initial step in mucin breakdown. The data suggest a new paradigm for mucin breakdown by the microbiota and the endo-mucinases provide a potential tool to explore changes that occur in mucin structure in intestinal disorders such as inflammatory bowel disease and colon cancer.

12 April 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
PDPeter William Dettmar
Peter William Dettmar
AWAndrew David Woodcock
Andrew David Woodcock
MWMatthew David Wilcox
Matthew David Wilcox
PCPeter Chater
Peter Chater
JPJeffrey Peter Pearson
Jeffrey Peter Pearson
Linked Content This article is linked to Race et al and Corfe et al papers. To view these articles, visit https://doi.org/10.1111/apt.15138 and https://doi.org/10.1111/apt.15225.